Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03438201
Other study ID # 77623917.0.0000.0065
Secondary ID
Status Not yet recruiting
Phase N/A
First received January 29, 2018
Last updated February 15, 2018
Start date April 4, 2018
Est. completion date April 30, 2020

Study information

Verified date February 2018
Source University of Sao Paulo
Contact Juliano P Almeida, Professor
Phone (5511) 98149-2592
Email doctorjuliano@yahoo.com.br
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Randomized Controlled Trial . The purpose of this study is to assess the hypothesis that whether a high protein diet combined with a physical activity protocol in surgical cancer patients admitted to the ICU in the post operative period is associated with better physical function at the hospital discharge as well as a better quality of life.


Description:

Surgical cancer patients will be categorized by their nutritional risk using a specific screening toll. During the hospital stay some measurements will be done. Such as resting energy expenditure (REE) before and after surgery; physical function evaluation; strength and quality of life.

The proposed intervention is a post operative diet with a different amount of protein (diet with a standard amount of protein and a diet with high amount of protein) associated to an institutional protocol of physical activity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 126
Est. completion date April 30, 2020
Est. primary completion date October 12, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Cancer patients

- Age greater than or equal to 18 years old

- Have a tendency to be admitted to the ICU after the surgery

- Fill the eligible criteria to start enteral feeding within 72 hours

- Sign the consent form;

Exclusion Criteria:

- Mechanical ventilation such as fraction of inspired oxygen inspired oxygen fraction (FiO2) >60% or positive end expiratory pressure (PEEP) > 12cm H2O

- Bronchopleural fistula

- Karnofsky <50

- Participant cannot b enrolled in another study

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Intervention
Enteral feeding that will give the patient the amount of protein between 2.0 - 2.5 Kg/body weight/Day
Control
Enteral feeding that will give the patient the amount of protein between 1.0 - 1.2 Kg/body weight/Day

Locations

Country Name City State
Brazil Faculty of Medicine University of Sao Paulo São Paulo SP

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Physical Function 6 minutes walk test 8 days after randomization
Secondary Physical Function 6-minute walk test after 30 days the date of randomization; 30 days after randomization
Secondary Quality of life Measurement of quality of life using the Euro-Qol 5D-5L index. EQ-5D-5L index includes five questions concerning mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A summary utility index value can be computed from subject's response to these five questions. Values range from -0.594 (worst possible health score) to 0 (death) to 1.000 (best health). 6 months after randomization
Secondary Body Composition related to prognosis Phase Angle (BIA) 8 days after randomization
Secondary Postoperative complications Clavien Dindo 30 days after randomization
Secondary Resting Energy Expenditure Indirect Calorimetry one day before surgery and one day after surgery
Secondary Length of hospital stay. Starts in the first day of hospitalization and ends on the day of hospital discharge 30 days after randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients